Detection methods of H7N9 avian influenza

Nucleic acid testing (NAT) is a general term for a series of technologies that directly detect pathogen nucleic acids. It can detect viral nucleic acids before antigens or antibodies are detected. Its basic steps include nucleic acid extraction. , amplification and detection. Genetic testing, often referred to as genetic testing, is a technology that detects DNA through blood, other body fluids, or cells. It can diagnose diseases and predict disease risks. Since nucleic acid testing directly detects pathogen nucleic acids, it has the advantages of high sensitivity, high specificity and a short detection window period, which can buy time for early diagnosis and treatment of epidemic diseases, reduce mortality and control the epidemic. Nucleic acid detection technology has developed from qualitative detection to real-time fluorescence quantitative detection. For some clinical needs, in addition to judging confirmed cases based on negative and positive cases, the degree of infection can also be judged based on the nucleic acid load. Detection equipment According to national standards, the fluorescence RT-PCR detection used for nucleic acid detection of H7N9 avian influenza virus requires a real-time fluorescence quantitative PCR instrument for quantitative detection, or a PCR gene amplification instrument for qualitative detection, and based on the H7N9 human infection with avian influenza PCR detection kit based on primers and probes developed for specific nucleic acid sequences.

On April 2, 2013, the National CDC has initiated logistics procedures to distribute nucleic acid detection PCR reagent probes and primers for detecting H7N9 avian influenza viruses to local CDCs and various diagnostic laboratories to ensure Accurate diagnosis of H7N9.

In late April 2013, the influenza A H7N9 virus RNA detection kit developed in Beijing has passed the national medical device emergency approval expert review and became the first batch of products in mainland China to enter the "green channel" for rapid approval. product. Clinical trials have shown that the kit can screen whether a person is infected with the H7N9 virus within two and a half hours, and will effectively ensure the prevention and control of influenza A (H7N9) virus.